Clinical Trials Browser

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00099086 2024-01-31

Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer

Phase 1 Completed

20 enrolled

Genitourinary

Prostatic Neoplasms

NCT00482807 2023-11-24

Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer

Phase 1 Completed

9 enrolled

Genitourinary

Prostatic Neoplasms

NCT00541047 2023-11-13

RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery

Phase 3 Completed

4,236 enrolled

GenitourinaryOther

Prostatic Neoplasms, Sexual Dysfunction, Physiological

NCT00651326 2023-08-04

DART

Phase 3 Terminated

48 enrolled

Genitourinary

Prostatic Neoplasms

NCT00866554 2023-06-02

Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy

Phase 2 Completed

60 enrolled

Genitourinary

Erectile Dysfunction, Prostatic Neoplasms, Lower Urinary Tract Symptoms

NCT00771017 2023-05-25

Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer

Phase 2 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT02058706 2023-05-10

LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

Phase 2 Completed

71 enrolled 18 charts

Genitourinary

Prostatic Neoplasms

NCT05019846 2023-04-18

SPA

Phase 3 Recruiting

310 enrolled

Genitourinary

Prostatic Neoplasms

NCT03043807 2023-02-16

A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy

Phase 2 Completed

26 enrolled 8 charts

Genitourinary

Prostatic Neoplasms

NCT00055731 2023-01-18

Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse

Phase 3 Completed

413 enrolled

Genitourinary

Prostatic Neoplasms

NCT00004124 2022-12-30

S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer

Phase 3 Completed

983 enrolled 13 charts

Genitourinary

Prostatic Neoplasms

NCT02064036 2022-10-18

CCRO025

Phase 1 Completed

17 enrolled

Genitourinary

Prostatic Neoplasms

NCT02716974 2022-08-04

oligo-mets

Phase 2 Completed

26 enrolled 8 charts

Genitourinary

Prostatic Neoplasms

NCT02582749 2022-07-11

Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases

Phase 2 Terminated

16 enrolled 6 charts

Genitourinary

Prostatic Neoplasms

NCT00002874 2022-06-15

Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy

Phase 3 Completed

840 enrolled 17 charts

Genitourinary

Prostatic Neoplasms

NCT00005044 2022-06-15

Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Phase 3 Completed

1,579 enrolled 13 charts

Genitourinary

Prostatic Neoplasms

NCT02614859 2022-03-29

BIMET-1

Phase 2 Completed

29 enrolled 10 charts

Genitourinary

Prostatic Neoplasms

NCT04248621 2021-07-29

Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients

Phase 4 Unknown

164 enrolled

Genitourinary

Prostatic Neoplasms

NCT00003653 2021-06-23

Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer

Phase 3 Completed

1,386 enrolled

Genitourinary

Prostatic Neoplasms

NCT03541928 2021-04-06

Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

Phase 2 Unknown

60 enrolled

Genitourinary

Prostatic Neoplasms

NCT03520478 2021-03-02

A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer

Phase 3 Unknown

654 enrolled

Genitourinary

Prostatic Neoplasms

Clinical Trials

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

VA STARPORT

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

ARCH

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

ARPEGGIO

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

S1216

STEEL

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

INTREPId (INTermediate Risk Erection PreservatIon Trial)

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Drugs-SNPs

Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer

Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer

Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

PCS III

A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer

Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer

RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery

DART

Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy

Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer

LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

SPA

A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy

Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse

S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer

CCRO025

oligo-mets

Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases

Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy

Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

BIMET-1

Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients

Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer

Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer